Lupus Anticoagulant and Abnormal Coagulation Tests in Patients with Covid-19

In this study, 20% of patients with Covid-19 had a prolonged activated partial-thromboplastin time. In 90% of these cases, the cause was lupus anticoagulant, with no associated bleeding. Patients with Covid-19 are susceptible to thromboses. The presence of a prolonged aPTT should, in general, not be...

Full description

Saved in:
Bibliographic Details
Published inThe New England journal of medicine Vol. 383; no. 3; pp. 288 - 290
Main Authors Bowles, Louise, Platton, Sean, Yartey, Nada, Dave, Minal, Lee, Kurtis, Hart, Daniel P, MacDonald, Vickie, Green, Laura, Sivapalaratnam, Suthesh, Pasi, K. John, MacCallum, Peter
Format Journal Article
LanguageEnglish
Published United States Massachusetts Medical Society 16.07.2020
Subjects
Adolescent
Adult
Aged
Aged, 80 and over
Anticoagulants
Anticoagulants - therapeutic use
Betacoronavirus
Blood Coagulation Tests
Coronavirus Infections - blood
Coronaviruses
Correspondence
COVID-19
Female
Humans
Lupus
Lupus Coagulation Inhibitor - blood
Male
Middle Aged
Pandemics
Partial Thromboplastin Time
Patients
Pneumonia, Viral - blood
Pulmonary embolisms
SARS-CoV-2
Severe acute respiratory syndrome coronavirus 2
Systemic lupus erythematosus
Thromboplastin
Thrombosis
Thrombosis - drug therapy
Young Adult
Online AccessGet full text
ISSN0028-4793
1533-4406
1533-4406
DOI10.1056/NEJMc2013656

Cover

More Information
Summary:In this study, 20% of patients with Covid-19 had a prolonged activated partial-thromboplastin time. In 90% of these cases, the cause was lupus anticoagulant, with no associated bleeding. Patients with Covid-19 are susceptible to thromboses. The presence of a prolonged aPTT should, in general, not be considered a contraindication to anticoagulation.
Bibliography:SourceType-Scholarly Journals-1
ObjectType-Correspondence-1
content type line 14
content type line 23
Drs. Bowles and Platton contributed equally to this letter.
ISSN:0028-4793
1533-4406
1533-4406
DOI:10.1056/NEJMc2013656